|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400082295 |
|
最近更新日期: Date of Last Refreshed on: |
2024-03-26 11:22:39 |
|
注册时间: Date of Registration: |
2024-03-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
第二次全国早产儿围产期状况调查 |
|
Public title: |
The Second National Survey on the Perinatal Status of Preterm Neonates |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
第二次全国早产儿围产期状况调查 |
|
Scientific title: |
The Second National Survey on the Perinatal Status of Preterm Neonates |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
徐凤丹 |
研究负责人: |
孔祥永 |
|
Applicant: |
Xu Fengdan |
Study leader: |
Kong Xiangyong |
|
申请注册联系人电话: Applicant telephone: |
+86 158 9993 1013 |
研究负责人电话:
Study leader's |
+86 135 2293 4314 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
fengdanjiejie@126.com |
研究负责人电子邮件: Study leader's E-mail: |
sdkongxy@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省东莞市石龙西湖三路(南)68号 |
研究负责人通讯地址: |
北京东城区南门仓5号 |
|
Applicant address: |
No.68 in Xi Hu third road, Shilong Town, Dongguan, Guangdong,China |
Study leader's address: |
No.5, Nanmencang, Dongcheng District, Beijing,China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
东莞市第八人民医院(东莞市儿童医院) |
||
|
Applicant's institution: |
Dongguan Eighth People’s Hospital (Dongguan Children’s Hospital) |
||
|
研究负责人所在单位: |
解放军总医院第七医学中心 |
||
|
Affiliation of the Leader: |
The Seventh Medical Center of PLA General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-17 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院第七医学中心医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Seventh Medical Center of Chinese PLA General Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-02-27 00:00:00 | ||
|
伦理委员会联系人: |
万雷 |
||
|
Contact Name of the ethic committee: |
Wan Lei |
||
|
伦理委员会联系地址: |
北京市东城区南门仓5号 |
||
|
Contact Address of the ethic committee: |
No.5, Nanmencang, Dongcheng District, Beijing,China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6672 1027 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
解放军总医院第七医学中心 |
||||||||||||||||||||||
|
Primary sponsor: |
The Seventh Medical Center of PLA General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京东城区南门仓5号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.5, Nanmencang, Dongcheng District, Beijing,China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
NA |
||||||||||||||||||||||
|
研究疾病: |
早产儿发生率、并发症及管理现状分析 |
||||||||||||||||||||||
|
Target disease: |
Analysis of the incidence, complications, and management status of preterm neonates |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
流行病学研究 |
||||||||||||||||||||||
|
Study type: |
Epidemilogical research |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
(1)了解我国早产儿发生情况及危险因素、围产期干预措施、产母情况等。 (2)了解早产儿早期预后、并发症及其影响因素。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) To explore the incidence, risk factors, perinatal intervention measures and maternal conditions of Preterm Neonates in China. (2) To explore the early prognosis, complications, and influencing factors of Preterm Neonates. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
2023年1月1日 00:00~2023年12月31日 23:59在各参加协作医院的产科出生的所有胎龄<37周的早产儿,包括转科及未转科的,其中转入新生儿病房(包括普通新生儿病房和NICU)的为重点记录人群。 |
||||||||||||||||||||||
|
Inclusion criteria |
From 00:00 on January 1, 2023 to 23:59 on December 31, 2023, all Preterm Neonates with gestational age<37 weeks born in obstetrics at participating collaborative hospitals, including those who have been transferred or not, with those who have been transferred to neonatal wards (including general neonatal wards and NICUs) being the key recorded population. |
||||||||||||||||||||||
|
排除标准: |
由外院产科出生而转入协作医院新生儿病房的早产儿不纳入本研究。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Preterm Neonates born in the obstetrics department of another hospital and transferred to the neonatal ward of a collaborative hospital are not included in this study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-04-01 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-04-01 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束及相关论文发表后 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the research is completed and relevant papers are published. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |